Novavax (NVAX) shares were up over 16% in recent Thursday trading after the company reported it swung to Q1 net income of $2.93 per diluted share from a net loss of $1.05 a year earlier.
Three analysts polled by FactSet expected a loss of $0.42.
Revenue for the quarter ended March 31 was $666.7 million, up from $93.9 million a year earlier.
Two analysts surveyed by FactSet expected $91.7 million.
The drugmaker said it expects 2025 adjusted total revenue of between $975 million and $1.03 billion.
Price: 6.93, Change: +0.98, Percent Change: +16.47
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.